0
0
New Delhi, India – In a significant move to tackle the nation’s growing obesity and diabetes crisis, the weight loss drug Mounjaro (tirzepatide) has been approved for use in India by the Central Drugs Standard Control Organisation (CDSCO). Developed by pharmaceutical giant Eli Lilly and Co., Mounjaro offers a potential new avenue for weight management, but experts caution about potential side effects and the importance of holistic approaches.
With nearly 100 million Indians grappling with obesity and diabetes, the demand for effective treatments is urgent. Obesity significantly elevates the risk of severe health conditions like cardiovascular disease and cancer. Mounjaro, a GLP-1 receptor agonist, works by slowing digestion and suppressing appetite, leading to weight loss. Clinical studies indicate users can lose between 16% to 23% of their body weight within 65 to 72 weeks.
However, Dr. Vanita Rahman, an internal medicine physician and weight-loss expert with the Physicians Committee for Responsible Medicine (PCRM), highlights both the benefits and limitations of Mounjaro. “GLP-1 agonists work by slowing digestion and suppressing appetite, leading to weight loss. But, after stopping the medication, most individuals regain the lost weight,” she explains. “These drugs do not address the underlying drivers of obesity, such as food nutrient density and emotional eating.”
Dr. Rahman also points to potential side effects, including gastrointestinal discomfort like nausea, constipation, and abdominal pain. “Some studies have also raised concerns about potential vision problems, suggesting a seven-fold increase in the risk of a serious eye condition that can lead to blindness. Furthermore, some patients may develop gallbladder disease,” she warns. “Since these medications are relatively new, their long-term safety remains unclear.”
The high cost of Mounjaro, ranging from Rs 14,000 to Rs 17,000 per month, also presents a significant barrier for many. Dr. Rahman notes that research shows nearly two out of three users discontinue the medication within 12 months due to side effects, cost, and limited effectiveness.
Instead, Dr. Rahman advocates for a holistic approach to weight management, emphasizing lifestyle changes, particularly dietary modifications. “A whole-food, plant-based diet enhances insulin sensitivity, supports heart health, and promotes sustainable weight loss without the risks and costs associated with medication,” she says. The BROAD study, she notes, found that participants on a plant-based diet lost an average of 12 kg in six months and maintained the weight loss at 12 months.
“Given the risks and limitations of GLP-1 agonists, patient well-being must remain the priority,” Dr. Rahman concludes. “Before starting these medications, it is crucial for patients to discuss potential risks and benefits with their healthcare providers. Individuals struggling with weight management should be educated about the challenges and limitations of these treatments. While weight-loss drugs may seem like a quick fix, the evidence strongly supports lifestyle-based interventions as the safest, most effective, and sustainable solution to combat obesity and its associated health risks in India.”
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult with a qualified healthcare professional before starting any weight loss medication or making significant lifestyle changes. The information provided is based on expert opinions and available studies, but individual results may vary. The long-term safety and efficacy of Mounjaro are still being studied.
